Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019062790) NOVEL CONJUGATES AND USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/062790 International Application No.: PCT/CN2018/107800
Publication Date: 04.04.2019 International Filing Date: 27.09.2018
IPC:
C07K 19/00 (2006.01) ,A61K 38/19 (2006.01) ,A61K 39/00 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
19
Hybrid peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
19
Cytokines; Lymphokines; Interferons
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
LAN, Keng-Li [CN/CN]; CN
TSAI, Cheng-Liang [CN/CN]; CN
Inventors:
LAN, Keng-Li; CN
TSAI, Cheng-Liang; CN
Agent:
NTD PATENT AND TRADEMARK AGENCY LIMITED; 10th Floor, Tower C, Beijing Global Trade Center, 36 North Third Ring Road East, Dongcheng District Beijing 100013, CN
Priority Data:
62/565,50929.09.2017US
Title (EN) NOVEL CONJUGATES AND USES THEREOF
(FR) NOUVEAUX CONJUGUÉS ET UTILISATIONS ASSOCIÉES
Abstract:
(EN) Provided herein are novel conjugates and pharmaceutical compositions comprising the novel conjugate described herein. The use of the novel conjugate to inhibit the growth of cancer cells and induce antibody production in a subject in need of cancer treatment, with or without an anti-cancer agent, is also provided.
(FR) L'invention concerne de nouveaux conjugués et des compositions pharmaceutiques comprenant le nouveau conjugué. L'invention concerne également l'utilisation du nouveau conjugué pour inhiber la croissance de cellules cancéreuses et induire la production d'anticorps chez un sujet en ayant besoin d'un traitement anticancéreux, avec ou sans agent anticancéreux.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)